MM-359 Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients

Autor: Patel, Krina, Rodríguez-Otero, Paula, Nooka, Ajay K., Callander, Natalie S., Solomon, Scott R., Baz, Rachid, Sborov, Douglas W., Gergis, Usama, Badros, Ashraf Z., Giralt, Sergio A., Pearse, Roger, Abonour, Rafat, Siegel, David S., Larson, Sarah M., Munshi, Nikhil C., Truppel-Hartmann, Anna, Bhatnagar, Rashmi, Wu, Fan, Piasecki, Julia, Felten, Jasper, Caia, Andrea, Cook, Mark, Popa, Mihaela, Jagannath, Sundar, Ailawadhi, Sikander
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S551-S552
Databáze: ScienceDirect
Externí odkaz: